| Autor: |
Marieke Pape, Linde M. Veen, Thom M. Smit, Steven C. Kuijper, Pauline A.J. Vissers, Elisabeth D. Geijsen, Peter S.N. van Rossum, Mirjam A.G. Sprangers, Sarah Derks, Rob H.A. Verhoeven, Hanneke W.M. van Laarhoven |
| Jazyk: |
angličtina |
| Rok vydání: |
2023 |
| Předmět: |
|
| Zdroj: |
Pape, M, Veen, L M, Smit, T M, Kuijper, S C, Vissers, P A J, Geijsen, E D, van Rossum, P S N, Sprangers, M A G, Derks, S, Verhoeven, R H A & van Laarhoven, H W M 2023, ' Late Toxicity and Health-Related Quality of Life Following Definitive Chemoradiotherapy for Esophageal Cancer : A Systematic Review and Meta-analysis ', International Journal of Radiation Oncology Biology Physics . https://doi.org/10.1016/j.ijrobp.2023.05.025 |
| Popis: |
Purpose: Definitive chemoradiotherapy (dCRT) is a treatment option with curative intent for patients with esophageal cancer that could result in late toxicities and affect health-related quality of life (HRQoL). This study aimed to review the literature and perform a meta-analysis to investigate the effect of dCRT on late toxicities and HRQoL in esophageal cancer. Methods and Materials: A systematic search was performed in MEDLINE, EMBASE, and PsychINFO. Prospective phase II and III clinical trials, population-based studies, and retrospective chart reviews investigating late toxicity or HRQoL after dCRT (≥50 Gy) were included. The HRQoL outcomes were analyzed using linear mixed-effect models with restricted cubic spline transformation. Any HRQoL changes of ≥10 points were considered clinically relevant. The risk of toxicities was calculated using the number of events and the total study population. Results: Among 41 included studies, 10 assessed HRQoL and 31 late toxicity. Global health status remained stable over time and improved after 36 months compared with baseline (mean change, +11). Several tumor-specific symptoms, including dysphagia, eating restrictions, and pain, improved after 6 months compared with baseline. Compared with baseline, dyspnea worsened after 6 months (mean change, +16 points). The risk of any late toxicity was 48% (95% CI, 33%-64%). Late toxicity risk of any grade for the esophagus was 17% (95% CI, 12%-21%), pulmonary 21% (95% CI, 11%-31%), cardiac 12% (95% CI, 6%-17%), and any other organ 24% (95% CI, 2%-45%). Conclusions: Global health status remained stable over time, and tumor-specific symptoms improved within 6 months after dCRT compared with baseline, with the exception of dyspnea. In addition, substantial risks of late toxicity were observed. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
